These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28592703)

  • 21. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
    Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
    BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of atypical
    Gossili F; Almasi CE; Zacho HD
    Hell J Nucl Med; 2023; 26(2):94-98. PubMed ID: 37527044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous
    Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
    Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
    Sato K; Qian J; Slezak JM; Lieber MM; Bostwick DG; Bergstralh EJ; Jenkins RB
    J Natl Cancer Inst; 1999 Sep; 91(18):1574-80. PubMed ID: 10491435
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Duan H; Moradi F; Davidzon GA; Liang T; Song H; Loening AM; Vasanawala S; Srinivas S; Brooks JD; Hancock S; Iagaru A
    Lancet Oncol; 2024 Apr; 25(4):501-508. PubMed ID: 38423030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
    Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of
    Ferraro DA; Garcia Schüler HI; Muehlematter UJ; Eberli D; Müller J; Müller A; Gablinger R; Kranzbühler H; Omlin A; Kaufmann PA; Hermanns T; Burger IA
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):652-664. PubMed ID: 31802175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of
    Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
    J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection Threshold and Reproducibility of
    Lückerath K; Stuparu AD; Wei L; Kim W; Radu CG; Mona CE; Calais J; Rettig M; Reiter RE; Czernin J; Slavik R; Herrmann K; Eiber M; Fendler WP
    J Nucl Med; 2018 Sep; 59(9):1392-1397. PubMed ID: 29602819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 33. Diagnostic Performance of
    Margel D; Bernstine H; Groshar D; Ber Y; Nezrit O; Segal N; Yakimov M; Baniel J; Domachevsky L
    Radiology; 2021 Nov; 301(2):379-386. PubMed ID: 34463555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer.
    Al Jalali V; Wasinger G; Rasul S; Grubmüller B; Wulkersdorfer B; Balber T; Mitterhauser M; Simon J; Hacker M; Shariat S; Egger G; Zeitlinger M
    J Nucl Med; 2023 Jun; 64(6):863-868. PubMed ID: 36657982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
    Mark HF; Samy M; Santoro K; Mark S; Feldman D
    Exp Mol Pathol; 2000 Feb; 68(1):65-9. PubMed ID: 10640455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
    Dewes S; Schiller K; Sauter K; Eiber M; Maurer T; Schwaiger M; Gschwend JE; Combs SE; Habl G
    Radiat Oncol; 2016 May; 11():73. PubMed ID: 27229485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [
    Lu Q; Long Y; Fan K; Shen Z; Gai Y; Liu Q; Jiang D; Cai W; Wan C; Lan X
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4000-4013. PubMed ID: 35763056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene.
    Song X; Zhang Y; Lv X; Xu Z; Long Y; Gai Y; Jiang D; Lei P; Lan X
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):965-977. PubMed ID: 37971500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
    Budäus L; Leyh-Bannurah SR; Salomon G; Michl U; Heinzer H; Huland H; Graefen M; Steuber T; Rosenbaum C
    Eur Urol; 2016 Mar; 69(3):393-6. PubMed ID: 26116958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.